male reproductive organ cancer: A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly males |
226754 |
2. Check conditionsNone |
226754 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
149 |
4. Check minimum number of eventsNone |
149 |
5. Include endpointsNone |
149 |
6. Filter based on genotype QC (FinnGen only) |
144 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D29
- Name in latin
- Neoplasma benignum scroti
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Scrotum
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of male genital organs
- Benign neoplasms
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1111 | - | 1111 |
| Only index persons | 936 | - | 936 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.04 | - | 0.04 |
| Median age at first event (years) | |||
| Whole population | - | - | 43.64 |
| Only index persons | - | - | 40.66 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 144 | - | 144 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 47.79 | - | 47.79 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 149
- Matched controls
- 1490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.4
ICD-10 Finland
Benign neoplasm: Scrotum
+∞
137.7
110
*
22288
ICD-8 Finland
Benign neoplasm of male genital organs, Loco alio definito
+∞
26.9
25
*
22280
ICD-8 Finland
Benign neoplasm of male genital organs, Scroti
+∞
12.7
12
*
KFD70
NOMESCO Finland
Excision of lesion of skin of scrotum
+∞
8.4
8
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
4.9
7.4
17
38
KFW96
NOMESCO Finland
Other operation on scrotum or scrotal organs
+∞
7.3
7
*
L72.1
ICD-10 Finland
Trichilemmal cyst
4.4
7.1
19
48
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
13.3
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
107
852
1.91
3.12
7.1
8.4
80.53
77.71
u/l
0.18
99
813
100
783
1.84
3.04
3.6
3.8
11.43
11.95
mm/h
0.12
87
730
111
916
1.83
2.63
3.6
3.7
1.93
2.03
mu/l
0.35
100
830
7
15
4.84
2.63
1.9
5.2
63.71
52.53
%
—
7
15
55
380
1.71
2.44
3.3
2.4
165.30
197.75
ug/l
0.62
50
348
55
387
1.67
2.25
1.9
1.9
84.35
87.57
pmol/l
0.19
30
218
16
74
2.30
2.24
3.6
2.7
72.45
63.11
ml/min/173m2
0.66
11
36
63
460
1.64
2.23
6.0
5.7
35.11
35.69
g/l
0.30
55
435
84
662
1.62
2.17
4.8
5.2
6.31
6.93
mmol/l
3.08
78
633
49
338
1.67
2.15
1.9
2.2
78.08
72.62
nmol/l
0.70
42
303
122
1065
1.80
2.05
15.7
13.6
83.04
82.35
ml/min/173m2
0.12
103
876
35
226
1.72
1.94
1.5
1.9
441.39
411.22
pmol/l
0.36
28
199
72
563
1.54
1.82
21.0
14.0
1.49
1.28
inr
1.00
33
159
36
239
1.67
1.80
2.3
1.8
2.74
3.02
mg/l
0.33
27
211
99
832
1.57
1.79
4.3
4.7
1.68
2.41
ug/l
1.00
90
748
86
707
1.51
1.67
3.0
2.9
14.42
14.80
pmol/l
0.77
79
630
123
1097
1.69
1.65
16.8
15.1
27.55
26.43
mg/l
0.11
103
883
64
498
1.50
1.61
6.4
7.8
1.22
1.20
mmol/l
1.86
49
432
75
608
1.47
1.51
9.1
10.5
3.97
4.18
e9/l
0.42
66
534
29
191
1.64
1.49
1.4
1.7
1036.66
1185.33
nmol/l
0.44
20
147
80
660
1.46
1.46
2.3
2.8
—
—
—
0
0
131
1202
1.74
1.40
10.5
10.7
30.03
30.18
u/l
0.03
123
1164
41
301
1.50
1.33
3.2
3.0
1.09
0.51
e6/l
0.23
35
222
61
485
1.44
1.32
2.4
2.7
—
—
—
0
0
13
71
1.91
1.24
4.8
6.1
25.31
24.78
mmol/l
0.15
13
71
58
467
1.40
1.14
5.9
6.4
1.23
1.20
mmol/l
2.30
50
432
124
1147
1.48
0.99
4.9
5.0
2.63
2.72
mmol/l
0.40
113
1059
7
36
1.99
0.98
1.3
1.3
40.60
38.32
g/l
—
7
30
29
211
1.46
0.98
4.1
3.6
552.54
170.75
ng/l
0.32
24
177
134
1262
1.61
0.95
24.9
21.4
41.08
41.81
%
0.70
126
1189
91
803
1.34
0.95
3.1
3.6
60.26
58.53
u/l
0.07
82
758
33
249
1.42
0.93
1.9
2.6
—
—
—
0
0
13
79
1.71
0.91
1.5
1.4
—
—
—
0
0
43
343
1.36
0.87
3.0
3.2
3206.06
1048.89
ng/l
1.27
33
285
115
1058
1.38
0.87
7.0
6.0
40.61
40.70
mmol/mol
0.03
105
994
8
45
1.82
0.86
1.3
1.4
7.24
7.08
g/l
—
8
39
8
45
1.82
0.86
1.3
1.4
3.28
3.41
g/l
—
8
39
8
45
1.82
0.86
1.3
1.4
—
—
—
0
0
0
25
0.00
0.80
0.0
1.7
—
—
—
0
0
121
1129
1.38
0.78
4.6
4.6
4.34
4.48
mmol/l
0.81
114
1053
7
39
1.83
0.73
1.3
1.5
0.00
0.94
g/l
—
7
34
7
40
1.79
0.72
1.1
2.3
—
—
—
0
0
116
1080
1.33
0.72
4.8
4.7
6.04
6.15
mmol/l
0.39
103
992
7
41
1.74
0.71
1.3
1.4
2.89
2.89
g/l
—
7
35
48
401
1.29
0.70
3.3
3.1
—
—
—
0
0
128
1211
1.40
0.70
19.4
17.5
89.33
86.63
umol/l
0.30
128
1211
118
1110
1.30
0.61
4.1
4.1
1.36
1.39
mmol/l
0.19
110
1030
0
20
0.00
0.61
0.0
2.3
—
—
—
0
0
0
21
0.00
0.60
0.0
2.2
—
—
—
0
0
19
141
1.40
0.60
3.6
4.1
203.79
242.39
u/l
2.05
19
132
43
362
1.26
0.59
3.8
4.2
4.09
8.52
mg/mmol
1.37
29
259
34
278
1.29
0.58
1.6
1.7
1.67
1.51
mmol/l
0.48
28
233
11
73
1.55
0.58
1.5
1.9
—
—
—
0
0
6
37
1.65
0.56
1.0
1.3
—
—
—
0
0
25
197
1.32
0.56
2.9
2.2
11.77
14.20
nmol/l
1.19
20
182
38
318
1.26
0.55
4.3
3.5
2.36
2.33
mmol/l
1.42
33
285
9
135
0.65
0.54
1.8
1.4
—
—
—
0
0
119
1127
1.28
0.53
4.7
4.5
1.27
1.30
mmol/l
0.28
109
1045
30
248
1.26
0.48
1.5
1.5
18.62
19.36
nmol/l
0.09
25
214
33
278
1.24
0.45
3.2
3.2
0.00
0.01
estimate
0.49
14
86
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
1.45
—
0
6
74
681
1.17
0.40
3.7
4.2
20.35
20.85
%
0.12
36
320
9
67
1.37
0.39
1.6
1.8
—
—
—
0
0
54
489
1.16
0.35
2.7
2.9
0.55
0.74
ug/l
1.98
36
322
27
230
1.21
0.34
1.6
1.6
0.64
1.56
mg/l
2.60
20
183
45
404
1.16
0.32
3.2
3.3
—
—
—
0
0
8
110
0.71
0.30
2.1
1.8
—
—
—
0
0
8
63
1.28
0.28
1.5
1.8
—
—
—
0
0
55
506
1.14
0.28
3.0
3.2
0.00
0.01
estimate
0.50
14
99
5
37
1.36
0.24
1.6
1.4
—
—
—
0
0
5
39
1.29
0.23
1.0
1.0
—
—
—
0
0
5
40
1.26
0.22
1.2
1.6
—
—
—
0
0
5
41
1.23
0.22
4.0
2.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
184.55
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
4.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
3.94
—
0
13
0
13
0.00
0.21
0.0
4.6
—
—
—
0
0
16
137
1.19
0.19
5.8
4.6
27.00
28.99
%
—
10
97
55
516
1.10
0.19
3.0
3.2
0.00
0.00
estimate
-0.00
14
85
54
507
1.10
0.19
3.9
4.4
0.00
0.00
estimate
-0.00
14
94
17
194
0.86
0.18
1.2
1.3
4.48
1.07
u/ml
—
6
60
50
475
1.08
0.13
4.0
3.9
65.76
48.99
ng/l
0.19
36
346
17
152
1.13
0.13
6.2
7.7
103.71
104.30
mmol/l
0.29
17
152
34
321
1.08
0.10
2.6
2.8
386.43
5340.46
umol/l
1.04
28
277
13
118
1.11
0.07
1.3
1.2
7.06
15.40
u/ml
—
5
47
8
90
0.88
0.07
1.6
1.6
—
—
—
0
0
8
93
0.85
0.07
1.3
1.8
390.75
362.22
nmol/l
—
8
83
20
188
1.07
0.06
1.4
2.1
—
—
—
0
0
13
141
0.91
0.05
8.8
8.4
12.44
11.40
kpa
0.32
13
136
13
138
0.94
0.02
1.5
2.0
—
—
—
0
0
13
123
1.06
0.01
3.6
8.3
—
—
—
0
0
12
127
0.94
0.01
4.2
3.1
—
—
—
0
0
14
136
1.03
0.00
1.4
1.9
—
—
—
0
0
19
189
1.01
0.00
3.8
2.7
0.54
0.38
e6/l
0.28
12
106
20
195
1.03
0.00
3.5
2.6
0.85
0.77
e6/l
0.07
11
111
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
9.78
—
0
9
13
130
1.00
-0.00
1.2
1.3
20.94
35.11
iu/ml
—
5
39
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
6.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
10.60
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
112.40
—
0
5
0
6
0.00
-0.00
0.0
6.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
65.38
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
17.96
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_SCROTUM and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_SCROTUM | 1.306 [0.98, 1.74] | 0.067 |
| Birth year | 0.985 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 605 males with CD2_BENIGN_SCROTUM died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_SCROTUM.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.253% |
| 5 | No data | 1.561% |
| 10 | No data | 3.61% |
| 15 | No data | 6.871% |
| 20 | No data | 11.442% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_SCROTUM – Benign neoplasm: Scrotum
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data